Goldman Sachs Group Inc Exelixis, Inc. Transaction History

Goldman Sachs Group Inc

$706 Billion
Q2 2025

A detailed history of Goldman Sachs Group Inc transactions in Exelixis, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 2,288,109 shares of EXEL stock, worth $79 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,288,109

Previous 1,466,779 56.0%

Holding current value

$79 Million

Previous $54.2 Million 86.25%

% of portfolio

0.01%

Previous 0.01%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$34.13 - $46.26 $28 Million - $38 Million	821,330 Added 56.0%	2,288,109 $101 Million
Q1 2025 May 09, 2025	BUY	$32.38 - $39.16 $2.21 Million - $2.67 Million	68,133 Added 4.87%	1,466,779 $54.2 Million
Q4 2024 Feb 11, 2025	BUY	$25.39 - $36.46 $10.9 Million - $15.7 Million	430,136 Added 44.41%	1,398,646 $46.6 Million
Q3 2024 Nov 14, 2024	SELL	$21.96 - $27.6 $4.14 Million - $5.2 Million	-188,299 Reduced 16.28%	968,510 $25.1 Million
Q2 2024 Aug 13, 2024	BUY	$20.34 - $23.73 $5.1 Million - $5.94 Million	250,525 Added 27.64%	1,156,809 $26 Million
Q1 2024 May 15, 2024	SELL	$20.17 - $23.93 $2.87 Million - $3.41 Million	-142,525 Reduced 13.59%	906,284 $21.5 Million
Q4 2023 Feb 13, 2024	BUY	$19.25 - $24.13 $112,285 - $140,750	5,833 Added 0.56%	1,048,809 $25.2 Million
Q3 2023 May 14, 2024	SELL	$19.04 - $22.74 $111,060 - $132,642	-5,833 Reduced 0.56%	1,042,976 $22.8 Million
Q3 2023 Nov 14, 2023	BUY	$19.04 - $22.74 $230,612 - $275,426	12,112 Added 1.17%	1,042,976 $22.8 Million
Q2 2023 May 14, 2024	BUY	$18.17 - $20.48 $1.14 Million - $1.29 Million	62,877 Added 6.5%	1,030,864 $19.7 Million
Q2 2023 Aug 14, 2023	BUY	$18.17 - $20.48 $1.14 Million - $1.29 Million	62,877 Added 6.5%	1,030,864 $19.7 Million
Q1 2023 May 14, 2024	SELL	$16.3 - $19.41 $54.9 Million - $65.4 Million	-3,370,235 Reduced 77.69%	967,987 $18.8 Million
Q1 2023 May 11, 2023	SELL	$16.3 - $19.41 $54.9 Million - $65.4 Million	-3,370,235 Reduced 77.69%	967,987 $18.8 Million
Q4 2022 May 14, 2024	SELL	$14.96 - $17.39 $5.98 Million - $6.95 Million	-399,578 Reduced 8.43%	4,338,222 $69.6 Million
Q4 2022 Feb 13, 2023	SELL	$14.96 - $17.39 $5.98 Million - $6.95 Million	-399,578 Reduced 8.43%	4,338,222 $69.6 Million
Q3 2022 May 14, 2024	BUY	$15.68 - $22.27 $5.82 Million - $8.26 Million	370,979 Added 8.5%	4,737,800 $74.3 Million
Q3 2022 Nov 10, 2022	BUY	$15.68 - $22.27 $5.82 Million - $8.26 Million	370,979 Added 8.5%	4,737,800 $74.3 Million
Q2 2022 May 14, 2024	BUY	$17.44 - $23.16 $57.9 Million - $76.8 Million	3,318,012 Added 316.36%	4,366,821 $90.9 Million
Q2 2022 Aug 15, 2022	BUY	$17.44 - $23.16 $19.5 Million - $25.9 Million	1,116,580 Added 34.35%	4,366,821 $90.9 Million
Q1 2022 May 16, 2022	BUY	$17.03 - $22.67 $8.86 Million - $11.8 Million	520,205 Added 19.05%	3,250,241 $73.7 Million
Q4 2021 Feb 14, 2022	BUY	$15.84 - $21.88 $1.4 Million - $1.93 Million	88,229 Added 3.34%	2,730,036 $49.9 Million
Q3 2021 Nov 10, 2021	BUY	$16.3 - $21.14 $43.1 Million - $55.8 Million	2,641,807 New	2,641,807 $55.8 Million

Others Institutions Holding EXEL

# of Institutions

687

Shares Held

259M

Call Options Held

1.41M

Put Options Held

1.55M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.1B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Exelixis, Inc. Transaction History